Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CLEO Diagnostics Ltd ( (AU:COV) ) has issued an announcement.
CLEO Diagnostics has notified the market of the issue of 833,333 unquoted options exercisable at $0.90 and expiring on 29 December 2028, under an existing arrangement previously disclosed via an Appendix 3B. The new options, which will not be quoted on the ASX, form part of the company’s broader capital management and incentive structure and may, if exercised, provide additional funding and further align stakeholders with the company’s long-term performance.
The most recent analyst rating on (AU:COV) stock is a Buy with a A$1.15 price target. To see the full list of analyst forecasts on CLEO Diagnostics Ltd stock, see the AU:COV Stock Forecast page.
More about CLEO Diagnostics Ltd
CLEO Diagnostics Ltd, listed on the ASX under the code COV, operates in the healthcare and diagnostics sector, focusing on the development and commercialisation of diagnostic technologies. The company targets medical markets where early and accurate detection can improve patient outcomes and support clinical decision-making.
Average Trading Volume: 255,151
Technical Sentiment Signal: Buy
Current Market Cap: A$80.95M
For detailed information about COV stock, go to TipRanks’ Stock Analysis page.